Digital Therapeutics Market worth $35.37 billion by 2031
The report "Digital Therapeutics/DTx Market by Offering (Software, Immersive), Application (Treatment (Diabetes, CNS, CVD, Rehab), Preventive), Revenue (Subscription, Enterprise), Channel (B2B, B2C), End User (Hospitals, Payers, Employers) - Global Forecast to 2031" is projected to reach USD 35.37 billion by 2031 from USD 10.95 billion in 2026, at a CAGR of 26.4% from 2026 to 2031.
Browse 300 market data Tables and 50 Figures spread through 400 Pages and in-depth TOC on "Digital Therapeutics/DTx Market, by Offering (Software, Immersive), Application (Treatment (Diabetes, CNS, CVD, Rehab), Preventive), Revenue (Subscription, Enterprise), Channel (B2B, B2C), End User (Hospitals, Payers, Employers) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/digital-therapeutics-market-51646724.html
The rapid rise in chronic diseases, aging populations, and healthcare workforce shortages is accelerating the adoption of digital therapeutics (DTx) as healthcare systems increasingly shift toward technology-enabled, patient-centric care. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20–79 years were living with diabetes globally in 2024, and this number is projected to reach 853 million by 2050, creating significant demand for scalable digital disease management solutions. Additionally, the Organisation for Economic Co-operation and Development (OECD) estimates that chronic diseases account for nearly 70% of healthcare expenditure across member countries, prompting governments and payers to invest in preventive and remote care technologies. The growing adoption of smartphones, connected medical devices, continuous glucose monitors (CGMs), wearable sensors, and AI-enabled clinical decision support systems is enabling digital therapeutics to deliver personalized, evidence-based interventions that improve medication adherence, patient engagement, and long-term clinical outcomes. Furthermore, regulatory initiatives such as the European Health Data Space (EHDS) Regulation, formally adopted in 2025, are expected to enhance secure cross-border health data exchange and interoperability, creating a stronger foundation for digital therapeutic deployment across Europe. Despite these favorable trends, market growth continues to be challenged by fragmented reimbursement frameworks, varying regulatory requirements across countries, cybersecurity and data privacy concerns, limited clinician awareness, and the need for robust real-world evidence demonstrating long-term clinical and economic benefits. Nevertheless, continued investments in AI-driven personalized care, remote patient monitoring, value-based healthcare, and digital health infrastructure are expected to accelerate the integration of digital therapeutics throughout the healthcare continuum.
By offering, the immersive & interface-based therapeutics segment is projected to grow at the highest CAGR during the forecast period.
In terms of offering, the immersive & interface-based therapeutics segment is expected to witness the fastest growth in the digital therapeutics market during the forecast period. This growth is driven by rapid advancements in virtual reality (VR), augmented reality (AR), mixed reality (MR), extended reality (XR), and sensor-enabled human–machine interfaces that enable highly interactive and personalized therapeutic experiences. These technologies are increasingly being adopted for pain management, neurological rehabilitation, mental health disorders, cognitive training, physical rehabilitation, and motor function recovery, where immersive environments have demonstrated the ability to improve patient engagement and clinical outcomes. Growing investments in digital neurotherapeutics, the emergence of AI-enabled adaptive therapy platforms, and the integration of haptic feedback, motion tracking, and wearable devices are further enhancing the effectiveness of these solutions. In addition, expanding clinical validation, greater acceptance of immersive therapies by healthcare providers, and the increasing availability of affordable XR hardware are expected to accelerate the adoption of immersive and interface-based therapeutics across both clinical and home care settings throughout the forecast period.
In 2025, the treatment & care-related applications segment accounted for the largest share of the digital therapeutics market.
By application, the treatment & care-related applications segment accounted for the largest share of the digital therapeutics market in 2025. This dominance is primarily attributed to the growing adoption of digital therapeutics as clinically validated interventions for the management of chronic and behavioral health conditions, including diabetes, cardiovascular diseases, respiratory disorders, mental health conditions, musculoskeletal disorders, and substance use disorders. The increasing prevalence of chronic diseases, coupled with rising healthcare costs and the need for continuous disease management, has accelerated the integration of digital therapeutics into routine clinical care. Healthcare providers, payers, and employers are increasingly adopting these solutions to improve treatment adherence, enable remote patient monitoring, support personalized care plans, and reduce hospitalizations and disease-related complications. In addition, the availability of robust clinical evidence, expanding reimbursement pathways, and greater integration of digital therapeutics with electronic health records, connected medical devices, and telehealth platforms have further strengthened the adoption of treatment-focused solutions, enabling this segment to maintain the largest market share in 2025.
Asia Pacific to be the fastest-growing market during the forecast period.
The digital therapeutics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing market for digital therapeutics, driven by rapid healthcare digitalization, increasing chronic disease burden, expanding smartphone connectivity, and supportive government-led digital health initiatives. Countries such as China, Japan, India, South Korea, Singapore, and Australia are investing significantly in digital healthcare infrastructure, telemedicine, artificial intelligence, and remote patient monitoring to improve healthcare accessibility and reduce the burden of chronic diseases. According to the GSMA's Mobile Economy Asia Pacific 2025 report, the region had 1.75 billion mobile internet subscribers in 2024, accounting for 64% of the population and providing a strong digital foundation for delivering app-based therapeutic interventions and connected care solutions. Furthermore, India's Ayushman Bharat Digital Mission (ABDM) has generated more than 810 million Ayushman Bharat Health Account (ABHA) IDs and linked over 518 million health records as of July 2026, significantly strengthening the country’s digital health ecosystem and interoperability. In addition, the World Health Organization (WHO) estimates that the South-East Asia Region accounts for nearly one-quarter of the global burden of noncommunicable diseases (NCDs), reinforcing the need for scalable digital solutions for chronic disease prevention and management. These factors, combined with increasing investments in digital health startups, expanding public-private collaborations, and favorable regulatory initiatives, are expected to accelerate the adoption of digital therapeutics across the Asia Pacific region.
Key Market Players:
The key players functioning in the digital therapeutics market include Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), Sword Health, Inc. (Portugal), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Digital Therapeutics/DTx Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
